Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$720,000 |
 |
Gilead SciencesGILD |
-$3.5B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$6.1M |
 |
Crispr TherapeuticsCRSP |
-$164M |
Are DURECT Insiders Buying or Selling?
DURECT (DRRX) has had no reported insider transactions in the past 90 days. The most recent was ASEN R SCOTT, who bought 5,917 shares at $1.92 on August 22, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the DRRX AI Score. For government officials trading this stock, see DRRX congressional trading.
Who’s Trading DURECT Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| ASEN R SCOTT | Bought $400,000 | 3 | Aug 22, 2025 |
Recent DURECT Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| ASEN R SCOTT | Aug 22, 2025 | Buy | 5,917 | $1.92 | $11,000 |
| ASEN R SCOTT | Aug 21, 2025 | Buy | 116,612 | $1.9 | $220,000 |
| ASEN R SCOTT | Aug 20, 2025 | Buy | 87,608 | $1.89 | $170,000 |
Frequently Asked Questions: DURECT Insider Trading
DURECT insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
ASEN R SCOTT has bought the most DRRX stock in the last 2 years, with a total value of $400,000.
According to our estimates, the total value of insider transactions for DURECT in the last 2 years is positive, amounting to $400,000. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
